Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12139492 | 0.81 | PLAU (0.48) | PLAUPOLBCHRNB2CHRNA4DAO | |
| SCHEMBL28874208 | 0.81 | PLAU (0.44) | PLAUKDM4EPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL9455975 | 0.78 | AXL (0.42) | CYP3A4 | |
| SCHEMBL10858069 | 0.77 | HPGD (0.41) | PLAUKDM4EPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL17682380 | 0.77 | PLAU (0.33) | PLAUCHRNB2CHRNA4 | |
| SCHEMBL17670982 | 0.77 | PLAU (0.37) | PLAUKDM4ECHRNB2CHRNA4RXFP1 | |
| SCHEMBL8122034 | 0.74 | VRK1 (0.34) | SMN1; SMN2DAO | |
| SCHEMBL10861616 | 0.74 | CYP3A4 (0.33) | PLAUKDM4ECYP3A4 | |
| SCHEMBL9330322 | 0.72 | DAO (0.41) | PLAUCHRNB2CHRNA4DAO | |
| SCHEMBL23611668 | 0.72 | PLAU (0.34) | PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115702132-A | Composition for enhancing nitrogen stabilizers, method and use thereof | 沃戴申生命科学美国有限责任公司 | 2023-02-14 | — | — | CN | claimed |
| CN-115397244-A | Nitrification inhibitor fungicide composition and use thereof | 沃戴申生命科学美国有限责任公司 | 2022-11-25 | — | — | CN | claimed |
| CN-114804481-A | Treatment method of pyridine-containing wastewater | 山东潍坊润丰化工股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-110514766-B | Method for determining trichloromethylpyridine in food | 中国检验检疫科学研究院 | 2022-03-01 | — | — | CN | claimed |
| CN-113056453-A | Trichloromethylpyridine compositions for enhanced nitrogen utilization and improved plant growth | 美国维德赛生命科学有限公司 | 2021-06-29 | — | — | CN | claimed |
| CN-107108383-B | Nitrification inhibitor composition and process for preparing same | 美国陶氏益农公司 | 2021-05-25 | — | — | CN | claimed |
| CN-111902042-A | Production method of sugarcane transplanting unit | 先正达参股股份有限公司 | 2020-11-06 | — | — | CN | claimed |
| CN-115702132-B | Composition for enhancing nitrogen stabilizer, method and use thereof | 沃戴申生命科学美国有限责任公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-119403445-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119095487-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-118434283-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-110637082-B | Bacillus isolates and uses thereof | 诺维信生物农业公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117715520-A | Compositions and methods for improving the rain tolerance of proteins on plant surfaces | 诺维信公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20120148661-A1 | HIGH BIOAVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY | PONIARD PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| EP-2418955-A1 | HIGH BIOAVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY | Poniard Pharmaceuticals, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120336-A1 | HIGH BIOAVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY | PONIARD PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100062056-A1 | ENCAPSULATED PICOPLATIN | PONIARD PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-2109451-A1 | ENCAPSULATED PICOPLATIN | Poniard Pharmaceuticals, Inc. (US) | 2009-10-21 | — | — | EP | disclosed |
| WO-2008097658-A1 | ENCAPSULATED PICOPLATIN | PONIARD PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-4594422-A | Hydroxylation of a 6-halo picolinic acid with a aqueous mineral acid solution; then halogenating | THE DOW CHEMICAL COMPANY (US) | 1986-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062056-A1 | ENCAPSULATED PICOPLATIN | PDCD2L, STOM, SLC46A1 | PLAU 2470/4885KDM4E 4851/4885POLB 1447/4885 |
| US-20120148661-A1 | HIGH BIOAVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY | PPIF, SLC30A5, SLC40A1 | PLAU 2734/4885KDM4E 3948/4885POLB 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.